Dupilumab as a Therapeutic Option in Chronic Eustachian Tube Dysfunction and Chronic Rhinosinusitis with Nasal Polyposis: A Case-Based Observation.

Authors

Holger Sudhoff

Published in

The journal of international advanced otology. Volume 22. Issue 5. Pages 1-4. Sep 21, 2026. Epub Sep 21, 2026.

Abstract

To report the first documented case of complete resolution of refractory dilatory Eustachian tube dysfunction (ETD) following dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP).
Four consecutive patients with longstanding refractory dilatory ETD, severe CRSwNP, and asthma, unresponsive to multiple sinus and mastoid surgeries, were treated with dupilumab.
Dupilumab resulted in complete remission of both CRSwNP and dilatory ETD symptoms within 6 weeks. Audiometry and tubomanometry confirmed restoration of middle ear function.
Dupilumab may offer a novel therapeutic option for patients with dilatory ETD associated with type 2 inflammation. Further prospective studies are needed to assess its long-term efficacy.

PMID:
42867349
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.